MedTrace Logo

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

NCT04588428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-01-22

Study results available
· View outcomes & findings →

Summary

The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study was divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.

Conditions

  • Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Interventions

DRUG

INO-4700

INO-4700 was administered ID.

DRUG

Placebo

Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.

DEVICE

CELLECTRA™ 2000

EP using the CELLECTRA™ 2000 device was administered following ID drug administration

DRUG

INO-4700

INO-4700

DEVICE

CELLECTRA™ 2000

CELLECTRA™ 2000

Sponsors & Collaborators

Principal Investigators

  • Bonaventure Orizu, MD · Inovio Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2023-01-19
Completion
2023-01-19
FDA Drug
Yes
FDA Device
Yes

Countries

  • Jordan
  • Kenya
  • Lebanon

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04588428 on ClinicalTrials.gov